Home  »  Companies   »  Selecta Biosciences Inc. (NASDAQ: SELB) Is Down -4...

Selecta Biosciences Inc. (NASDAQ: SELB) Is Down -47.55% Year-To-Date, Analysts Forecast Major Price Rally

Selecta Biosciences Inc. (NASDAQ:SELB) traded at $1.71 at close of the session on Tuesday, 09/20/22, made a downward move of -2.84% on its previous day’s price.

Looking at the stock we see that its previous close was $1.76 and the beta (5Y monthly) reads 0.94 with the day’s price range being $1.69 – $1.78. The company has a trailing 12-month PE ratio of 7.37. In terms of its 52-week price range, SELB has a high of $4.53 and a low of $0.65. The company’s stock has lost about -23.32% over that past 30 days.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

Selecta Biosciences Inc. has a market cap of $268.21 million and is expected to release its quarterly earnings report on Mar 09, 2022 – Mar 14, 2022. Estimates by analysts give the company expected earnings per share (EPS) of -$0.08, with the EPS growth for the year raised at -$0.09 for 2022 and -$0.45 for next year. These figures represent 59.10% and -400.00% growth in EPS for the two years respectively.

The median projection represents growth squeezing down to 93.30% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $67.7 million, or -20.40% down from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the SELB stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of Hold.

Based on estimates by 8 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Selecta Biosciences Inc. (SELB) stock as a Hold, while 8 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -8.97% off its SMA20 and -10.57% from its 50-day simple moving average. The RSI (14) is pointing at 41.07 while the volatility over the past week is 6.96% and jumps to 8.40% over the past one month. The beta value is 0.95, while the average true range (ATR) is currently pointing at 0.15.

Let’s briefly compare Selecta Biosciences Inc. (SELB) stock to its peers. We find that current price change of -2.84% and -58.99% over the past 12 months for SELB competes that of Pieris Pharmaceuticals Inc. (PIRS), which has seen its stock price fall -4.62% in the last trading session and was -77.41% over the last one year. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at -1.13% and -1.01%, respectively, at close of the trading.

Coming back to Selecta Biosciences Inc. (NASDAQ:SELB), we note that the average 3-month trading volume was 1.94 million, while that of the preceding 10-day period stands at 0.98 million. Current shares outstanding are 148.51 million.

The insiders hold 5.40% of the company’s shares while institutions hold 46.50%. The data shows that short shares as of Jul 14, 2022, stood at 6.36 million at a short ratio of 2.25. This represents a 4.19% short interest in shares outstanding on Jul 14, 2022. Shares short fall in July from the previous month at 8.62 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -47.55% down in year-to-date price movement.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]